Financials in USD. Standardized financial statements.
A compact view of how Rallybio Corporation turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Revenue? | $858,000 | $636,000 | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | +34.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $92,000 | $0 | $150,000 | $167,000 | $109,000 | $62,030 | $26,344 |
| Gross Profit? | $766,000 | $636,000 | -$150,000 | -$167,000 | -$109,000 | -$62,030 | -$26,344 |
| Gross Margin? | +89.3% | +100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $28.83M | $61.13M | $78.93M | $67.88M | $45.65M | $25.30M | $17.64M |
| Operating Income? | -$28.06M | -$60.50M | -$78.93M | -$67.88M | -$45.65M | -$25.30M | -$17.64M |
| EBITDA? | -$27.97M | -$60.37M | -$78.78M | -$67.72M | -$45.39M | -$25.24M | -$17.39M |
| Income Before Tax | -$8.98M | -$57.77M | -$74.56M | -$67.73M | -$47.01M | -$26.46M | -$17.46M |
| Income Tax Expense | $0 | $0 | $0 | -$1.07M | $0 | -$15,000 | $0 |
| Net Income? | -$8.98M | -$57.77M | -$74.56M | -$66.65M | -$47.01M | -$26.45M | -$17.63M |
| EPS? | $-1.59 | $-10.64 | $-14.72 | $-16.72 | $-11.68 | $-9.52 | $-4.40 |
| Diluted EPS? | $-1.59 | $-10.64 | $-14.72 | $-16.72 | $-11.68 | $-9.52 | $-6.32 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality